Nationwide Genomic Screening Network Can Be Effective in Identifying Rare Targetable Genetic Alterations

Conference Correspondent

Gedatolisib, a highly potent dual inhibitor of PI3K and mTOR, is expected to have an effect for tumors with PI3K/AKT/mTOR pathway alterations. However, these pathway alterations are rare in patients with small-cell lung cancer (SCLC). Researchers used a nationwide genomic screening network in Japan, known as LC-SCRUM–Japan, to identify patients with relevant mutations, and conducted a phase 2 study of gedatolisib.

A multicenter, single-arm, phase 2 study was conducted to evaluate the efficacy and safety of gedatolisib in patients with advanced SCLC who had genetic alterations in the PI3K/AKT/mTOR pathway. Patients who enrolled had SCLC and targetable genetic alterations that were identified after reviewing data from 154 cancer centers and hospitals in Japan. The primary end point of the phase 2 study was objective response rate, and the planned sample size was 19.

From July 2015 to March 2020, 1035 patients with SCLC were screened. Targetable genetic alterations were identified in 263 patients (25%), including the MYC family (10%), PI3K/AKT/mTOR (7%), RAS (3%), and EGFR (2%).

A total of 15 patients with genetic alterations in the PI3K/AKT/mTOR pathway (2.5% PIK3CA, 3.7% PTEN, and 0.9% other mutations) enrolled in the phase 2 study and received gedatolisib. Their median age was 64 years (range, 52-84 years); 10 patients were male, and 6 patients had received ≥2 prior chemotherapy regimens.

The overall response rate associated with gedatolisib was 0%, and the disease control rate was 20%. Median progression-free survival was 0.9 months (95% confidence interval [CI], 0.4-3 months). Median overall survival was 5.8 months (95% CI, 1.2-15.6 months).

The safety profile of gedatolisib was similar to previous reports. Treatment-related grade 3 adverse events, including hypertension, hypoalbuminemia, oral mucositis, ALT increase, and creatinine increase, were observed in 4 patients. Only 1 patient with PTEN I8fs mutation had durable stable disease after treatment with gedatolisib: their progression-free survival was 6.7 months.

Researchers concluded that use of a large-scale nationwide genomic screening network can be an effective way to identify rare targetable genetic alterations, despite the fact that this phase 2 study did not demonstrate clinical benefit of gedatolisib for patients with advanced SCLC who had genetic alterations in the PI3K/AKT/mTOR pathway.

Reference

  • Udagawa H, Ikeda T, Umemura S, et al. Phase II study of gedatolisib for small-cell lung cancer patients with genetic alterations in PI3K/AKT/mTOR pathway based on a large-scale nationwide genomic screening network in Japan (EAGLE-PAT/LC-SCRUM-Japan). J Clin Oncol. 2020;38:suppl (abstract 9064).
Related Articles
ASCO 2020 Lung Cancer Highlights
Conference Correspondent

Although the American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually because of the COVID-19 pandemic, hundreds of abstracts, posters, and presentations were still made available to inform clinicians on the latest developments in the treatment of lung cancer. This publication features some of the key highlights from the meeting, which can be used to improve the management and care of patients with the disease.

Impact of Immune-Related Adverse Events on Checkpoint Inhibitor Consolidation Therapy in Stage III NSCLC
Conference Correspondent
Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer.
Patterns of Acquired Resistance in Patients with NSCLC Who Receive PD-1 Inhibitors
Conference Correspondent
The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented.
Last modified: November 5, 2020

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code